Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

BioNTech SE

Moderna

The Omicron variant has made Wuhan based vaccines redundant, will replace Delta, and causes a milder version of covid. BioNTech, Novavax and Moderna will need to urgently develop an appropriate 2nd generation vaccine candidate.

COVID-19 Vaccines: The Big Omicron Reboot For BioNTech, Moderna And Novavax

NVAX stock is up in the air today ahead of an important WHO meeting to discuss approval of Novavax's vaccine EUA. Here's what to know.

NVAX Stock Is on Watch Ahead of WHO Meeting. Here's What to Know.

Boston, Massachusetts--(Newsfile Corp. - December 15, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

NVAX Investor Alert: Thornton Law Firm Reminds Novavax, Inc. Investors of Securities Class Action Lawsuit

RADNOR, Pa., Dec. 14, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX).

Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Novavax, Inc. of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Novavax, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - NVAX

The Serum Institute of India (SII) plans to launch the Novavax Inc (NASDAQ: NVAX) COVID-19 vaccine for children in India in six months, Adar Poonawalla said. The Novavax shot, called Covovax, has shown promising results in trials in three and older children, Adar Poonawalla told a virtual conference organized by the Confederation of Indian Industry.

Serum Institute's CEO Expects To Launch Novavax Vaccine For Kids In Six Months: Reuters

There are four reasons why this prediction makes sense.

Prediction: Novavax Stock Could Soar 20% or More Within the Next 20 Days

The war against the omicron variant is heating up, and NVAX stock holders can remain confident in Novavax's thorough and aggressive strategy. The post Bet on Novavax as Ambitious Battle Against Covid-19 Goes Global appeared first on InvestorPlace.

Bet on Novavax as Ambitious Battle Against Covid-19 Goes Global

Concerns about the omicron variant as well as some good news are helping drive these vaccine stocks higher.

Why BioNTech, Moderna, and Novavax Stocks Are Jumping Today

Ocugen, Inc.

Both of these companies are currently playing second fiddle to the leaders in the coronavirus-vaccine market.

Better Buy: Ocugen vs. Novavax

GAITHERSBURG, Md., Dec. 13, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it has submitted a regulatory filing to the Ministry of Health and Prevention (MoHaP) for emergency use of its COVID-19 vaccine in the United Arab Emirates (UAE).

Novavax Files for Emergency Use of COVID-19 Vaccine in the United Arab Emirates

Pfizer

Johnson & Johnson

It looks like the winners will keep winning.

What Does the Omicron Variant Mean for Vaccine Stocks?

Lawyers are scrutinizing the company, and they're not happy.

Why Novavax Plummeted by Over 6% Today

It's being simultaneously battered by setbacks and buoyed by optimism.

What in the World Is Going on With Novavax Stock?

Conventional wisdom suggests that if Novavax gets an EUA for its Covid-19 vaccine, it will be bullish for NVAX stock. That fact may not hold up to public opinion.

The Bullish Case for Novavax Stock Is Based on Opinion Not Fact

Inari Medical

Our Foolish roundtable has three stocks to invest in as we enter our third year of the COVID pandemic.

3 COVID-19 Stocks That Should Beat the Market in 2022

Novavax Inc. (NASDAQ:NVAX) shares were moving this week after the head of the Vaccines Task Force for the European Medicines Agency said Tuesday the company's COVID-19 vaccine could soon receive authorization in Europe. Novavax shares were down 1.05% at $179.83 Thursday afternoon.

Technical Takeaways From The Novavax Stock Chart

The markets have seen considerable volatility over the last week, as the world awaits more data on the apparently more infectious omicron strain of the novel coronavirus that has spread to several countries. Covid-19 vaccine developer Novavax's stock has seen particularly large swings as investors.

Does Omicron Help Or Hurt Novavax Stock?

Pubmatic

These companies are on the leading edge of innovation and can make patient investors a lot richer.

3 Game-Changing Stocks to Invest $1,000 in Right Now

San Francisco, California--(Newsfile Corp. - December 8, 2021) - Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now. Class Period: Mar. 2, 2021 - Oct. 19, 2021Lead Plaintiff Deadline: Jan. 11, 2022Visit: www.hbsslaw.com/investor-fraud/NVAXContact An Attorney Now: NVAX@hbsslaw.com844-916-0895Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax's progress toward successfully developing its COVID-19 vaccine (NVX-CoV2

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Novavax (NVAX) Investors to Lead Plaintiff Opportunity in Securities Fraud Class Action

The stock price of Novavax, Inc. (NASDAQ: NVAX) increased by 28.89% in the most recent trading session. This is why it happened.

Novavax Stock (NVAX): Why The Price Surged

ACADIA Pharma

Cellectis SA

Intellia Therapeutics

While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.

Good Stocks To Invest In Right Now? 4 Health Care Stocks To Check Out

Novavax Inc. (NASDAQ:NVAX) shares were trading higher Tuesday after the head of Vaccines Task Force for the European Medicines Agency reportedly said the company's COVID-19 vaccine could soon receive authorization in Europe. A final decision will take place next week, when it is expected the agency will approve the vaccine.

Novavax Stock Climbs Back Into Pattern On Vaccine News

Novavax Inc (NASDAQ:NVAX) is trading significantly higher Tuesday after the head of the Vaccines Task Force for the European Medicines Agency reportedly said the company's COVID-19 vaccine could soon receive authorization in Europe. The health official reportedly announced that the agency is likely to approve the Novavax vaccine by next week.

Why Novavax Shares Are Surging Today

New York, New York--(Newsfile Corp. - December 7, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline.SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or...

NVAX Notice: Rosen, Top Ranked Global Investor Counsel, Encourages Novavax, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NVAX

News for Novavax Stock (NVAX)